A Study of LP-118 in Patients With Advanced Tumors

Inclusion Criteria:

• Subjects with histologically or cytologically confirmed malignancy, including eitherof the following disease: relapsed or refractory lymphomas with at least onemeasurable disease based on Lugano 2014 criteria; or advanced or metastatic solidtumors based on RECIST V1.1 criteria.

• Subjects have a life expectancy of ≥12 weeks, and Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1.

• Subjects must have adequate bone marrow function independent of blood transfusion orgrowth factor support per local laboratory reference range at Screening.

• Subjects must have adequate coagulation, renal, and hepatic function, per locallaboratory reference range at Screening.

• All acute toxicity from previous anti-tumor treatment or surgery has been alleviatedto NCI CTCAE 5.0 ≤ Grade 1.

• All enrolled subjects should take medically approved contraceptives during theentire treatment period and within 90 days after the end of treatment.

• Volunteer and sign informed consent, willing to follow trial protocol.

Exclusion Criteria:

• Subjects who have undergone allogeneic or autologous hematopoietic stem celltransplantation or CAR-T cell therapy (except for lymphoma patients who had receivedautologous stem cell transplantation or CAR-T cell therapy before 90 days of thefirst dose of LP-118).

• Subjects who have received the following treatments within 4 weeks or 5 half-livesbefore the first dose of study drug:

• Antitumor therapies including myelosuppressive chemotherapy, targeted therapy,biological therapy and/or immunotherapy;

• Any investigational treatment;

• Patients who have undergone major surgery, severe trauma or radiotherapy.

• Subjects who have received the following treatments within 1 week before the firstdose of study drug:

• Steroids or traditional herbal medicine for antitumor purposes;

• Strong and moderate CYP3A inhibitors and inducers, grapefruit and grapefruitjuice;

• Any medications that can cause QTc interval prolongation or torsionaltachycardia.

• Solid tumor patients with ITP or AIHA.

• Subjects with known bleeding disease or with a history of non-chemotherapy inducedthrombocytopenic bleeding or ineffective platelet transfusion within 1 year beforethe first dose of study drug.

• Subjects with uncontrollable or CTCAE ≥ grade 2 gastrointestinal bleeding occurredwithin 90 days before the first dose of study drug.

• Subjects have received the therapeutic dose of anticoagulant or antiplatelet drugswithin 1 week before the first dose of study drug.

• Subjects have any serious and/or uncontrolled systemic disease.

• Subjects have poor cardiovascular function, in line with New York Heart Association (NYHA) cardiac function classification ≥ 2 or QTcF greater than 450ms (male) or 470ms (female) on ≥ 3 independent ECG.

• Subjects have disease states where clinical manifestations may be difficult tocontrol, including but not limited to HIV, HBV, HCV, syphilis positive or activebacterial and fungal infections.

• Lymphoma with primary central nervous system (CNS) malignancy or any disease affectsthe CNS.

• Any gastrointestinal conditions that may severely affect the study drug absorptionor pharmacokinetic parameters.

• Subjects who have known severe allergies to study drugs or any excipients.

• Subjects who have evidence of a second primary tumor.